Faculty

Publications:

• Mathur A, Maiers TA, Andrick, B. Impact of a pharmacist-led telehealth oral chemotherapy clinic. AJHP. 2022 May;79(11):896-903. doi: 10.1093/ajhp/zxac038. Link
• Gatson NTN, Makary M, Bross SP, Vadakara J, Maiers T, Mongelluzzo GJ, Leese EN, Brimley C, Fonkem E, Mahadevan A, Sarkar A, Panikkar R. Case series review of neuroradiologic changes associated with immune checkpoint inhibitor therapy. Neurooncol Pract. 2020 Nov; 8(3):247-258. doi: 10.1093/nop/npaa079. Link
• Andrick B, Potter A, Smith A, Maiers T, et al. Evaluation of chemotherapy induced nausea and vomiting for patients receiving post-transplant cyclophosphamide for matched related and unrelated donor stem cell transplant with ondansetron plus rolapitant antiemetic prophylaxis. Biology of Blood and Marrow Transplantation. 2020 March; 26(3): S391 - S392. Link

• “Panel: Best Practices in Hematology/Oncology Telepharmacy.” Hematology/Oncology Pharmacy Association Annual Conference 2022.
• “Oral Chemotherapy Supportive Care.” Pennsylvania Pharmacists Association Annual Virtual Conference 2020.

Publications:

• Hart K, Andrick B, Grassi S, Manikowski J, Graham J. Cancer-Associated Venous Thromboembolism Treatment With Anti-Xa Versus Weight-Based Enoxaparin: A Retrospective Evaluation of Safety and Efficacy. Ann Pharmacother. 2021;55(9):1120-1126. 

Presentations:

• "Cancer-Associated Venous Thromboembolism Treatment with Anti-Xa versus Weight-Based Enoxaparin: A Retrospective Evaluation of Safety and Efficacy." American College of Clinical Pharmacy Virtual Poster Symposium May 2020 and Eastern States Conference June 2020. 
• "Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma." Hematology/Oncology Pharmacy Association Journal Club November 2020. 
• “Evaluation of Pharmacist Intervention in Improving Documentation of Intrathecal Chemotherapy Administration in Pediatric Hematology/Oncology Patients.” American Society of Health-System Pharmacists Midyear Clinical Meeting December 2020.  
• “Development of Predictive Models for Steroid-Induced Hyperglycemia in Multiple Myeloma.” Eastern States Conference and Hematology/Oncology Pharmacy Association Annual Conference April 2021.

• Best Practices in Hematology/Oncology Telepharmacy." HOPA Annual Meeting 2022. Boston, MA 
• Andrick B, Mathur AD, Maiers T, Graham J, Vadakara J. Pharmacist Versus Physician Provider Management of Hydroxyurea Therapy for Polycythemia Vera (PERMANACE). American Society of Hematology Annual Meeting and Exposition (Virtual Meeting).
• Maiers TA, Carmichael JM, Mathur AD. Benefits of a health-system pharmacist-controlled oral chemotherapy medication therapy disease management program. Poster presented at: American Society of Health-System Pharmacists Midyear Clinical Meeting; Anaheim, CA
• Mathur AD, Carmichael JM, Maiers TA, Gionfriddo MR. Evaluation of glucocorticoid-induced hyperglycemia following dexamethasone premedication in patients receiving paclitaxel or docetaxel. Poster presented at: Hematology/Oncology Pharmacy Association Annual Conference; Denver, CO.
• Mathur AD, Sneidman RE, Carmichael JM. Determination of extended interval monitoring parameters in oncology patients receiving denosumab. Poster presented at: American Society of Health-System Pharmacists Midyear Clinical Meeting; Orlando, FL.
• Divakaruni A, Eckel SP, Stopper LA, Vogel VG. Monitoring and management of trastuzumab-induced cardiotoxicity at an outpatient cancer center. Poster presented at: American Society of Health-System Pharmacists Midyear Clinical Meeting; Las Vegas, NV. 

• Mathur AD, Maiers TA, Andrick BJ. Impact of a Pharmacist-Led Telehealth Oral Chemotherapy Clinic. American Journal of Health-System Pharmacy. 2022;zxac038. doi:10.1093/ajhp/zxac038. PMID: 35136920
• Lee GW, Mathur AD, Leese E, Andrick BJ, Gatson N. Pharmacist value-added to neuro-oncology subspecialty clinics: a pilot study uncovers best practices and optimal time utilization. J Oncol Pharm Pract. 2020;1078155220957738. doi: 10.1177/1078155220957738. Link
• Eslami A, Mathur AD, Jha KK, Wang, H. (2018). Acute liver failure secondary to ABVD use. BMJ Case Reports. 2018;2018: bcr2018225474. doi:10.1136/bcr-2018-225474 Link
• Divakaruni A., Saylor, E., & Duffy, A. P. (2018). Assessing the need for improved strategies and medication-related education to increase adherence for oral anticancer medications in the young adult oncology population. J Oncol Pharm Pract. 2018;24(5):337-342. Link

• Hua GT, Hart K, Mathur AD. “Comparison of the incidence of Pneumocystis jirovecii pneumonia infection with or without antipneumocystis prophylaxis in neuro-oncology patients receiving temozolomide.” Hematology/Oncology Pharmacy Association (HOPA) Annual Conference [National]; Boston, MA. March 2022. 
• Hua GT and Maiers T. “Evaluation of rapid-infusion protocol compliance for hematologic malignancies.” Presented at American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition [National]; Virtual. December 2021. 
• Hua GT and Heidenthal B. “Effects of a pharmacist-driven methicillin-resistant Staphylococcus aureus nasal culture protocol on antimicrobial stewardship in patients suspected of pneumonia.” Presented at ASHP Midyear Clinical Meeting and Exhibition [National]; Virtual. December 2020. 
• Hua GT, Poehler D, and Whitman A. “Co-prescription of opioids and benzodiazepines at the University of Virginia Cancer Center: a retrospective analysis.” Presented at ASHP Midyear Clinical Meeting and Exhibition [National]; Las Vegas, NV. December 2019. 
• Hua GT. “Managing pediatric diabetic ketoacidosis.” Presented at Virginia Society of Health-System Pharmacists Spring Seminar [State]; Williamsburg, VA. April 2021. 
• Hua GT. “Continuation of cannabidiol as non-formulary patient own supply therapy in the inpatient setting.” Presented at Virginia Society of Health-System Pharmacists Fall Seminar [State]; Williamsburg, VA. November 2019.

• Hua GT, Carlson D, Starr JR. Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma. J Adv Pract Oncol. 2022;13(7):717-723. doi:10.6004/jadpro.2022.13.7.8. Hua G, Scanlan R, Straining R, Carlson DS. Teclistamab-cqyv: The First Bispecific T-Cell Engager Antibody for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma. J Adv Pract Oncol. 2023;14(2):163-171. doi:10.6004/jadpro.2023.14.2.7

• “Machine Learning Approach to Venous Thromboembolism Prediction in Newly Diagnosed Patients with Cancer Receiving Chemotherapy.” Hematology/Oncology Pharmacy Association Annual Meeting Boston, MA; March 2022 
• “Predicting the future: Understanding clinical predictive models for cancer.” HOPA Annual Meeting 2021. Virtual.
• “Ambulatory hematology/oncology pharmacist documentation in Epic: moving beyond free text.” HOPA 2020 Practice Management Meeting Virtual.
• “Vaccines for HCT: An update on varicella zoster & influenza vaccines." TCT 2019 Conference; BMT Pharmacist Conference. Houston, TX.
• “A guide to individualized vaccinations needs of oncology patients.” Pennsylvania Pharmacist Association Midyear Meeting. Lancaster, PA.
• “Immunotherapy in metastatic melanoma.” Georgia Society of Health-System Pharmacists Webinar Presentation.

• Andrick B, Tusing L, Jones J, Hu Y, Sneidman R, Gregor C, Basu S, Lynch JP, Vadakara J. The impact of a hematopoietic cellular therapy pharmacist on clinical and humanistic outcomes: A RE-AIM framework analysis. Transplant Cell Ther. 2022 Feb 18:S2666-6367(22)00092-6. doi: 10.1016/j.jtct.2022.02.015. Epub ahead of print. PMID: 35189400.
• Okubo L, Andrick B, Rampulla R, Leri F. Smaller but more frequent dosing of cefepime in the treatment of febrile neutropenia. J Oncol Pharm Pract. 2022 Feb 14:10781552221080078. doi: 10.1177/10781552221080078. Epub ahead of print. PMID: 35156879. 
• Mathur A, Maiers T, Andrick B. Impact of Pharmacist-led Telehealth Oral Chemotherapy Clinic. Am J Health System Pharm. Am J Health Syst Pharm. 2022 Feb 5:zxac038. doi: 10.1093/ajhp/zxac038. Epub ahead of print. PMID: 35136920. 
• Gandhi A, Andrick B, Darling J, Truong T, Signorelli J. Oral Antineoplastics in Acute Myeloid Leukemia: A Comprehensive Review. Clinical Lymphoma, Myeloma and Leukemia. August 2022. Doi: https://doi.org/10.1016/j.clml.2022.08.005 
• Marjoncu D, Carmichael J, Andrick B, Oxenberg J. Assessment of hold-times for oral chemotherapy agents surrounding surgical procedures. JHOP. Accepted Pending Publication. July 2022.
• Hart K, Andrick B, Grassi S, Manikowski J, Graham J.  Cancer-Associated Venous Thromboembolism Treatment with Anti-Xa Versus Weight-Based Enoxaparin: A Retrospective Evaluation of Safety and Efficacy.  Ann Pharmacother. 2021 Jan 16:1060028020988362. doi: 10.1177/1060028020988362. Link
• Lee GW, Mathur AD, Leese E, Andrick B, Gatson N. Pharmacist value-added to neuro-oncology subspecialty clinics: a pilot study uncovers best practices and optimal time utilization. J Oncol Pharm Pract. 2020;1078155220957738. doi: 10.1177/1078155220957738. Link
• Andrick B, Potter A, Smith A, et al. Evaluation of chemotherapy induced nausea and vomiting for patients receiving post-transplant cyclophosphamide for matched related and unrelated donor stem cell transplant with ondansetron plus rolapitant antiemetic prophylaxis. Biol Blood Marrow Transplant. 2020 March; 26(3): S391 - S392. doi: https://doi.org/10.1016.j.bbmt.2019.12.319. Link
• Tahir S, Vadakara J, Lynch, J, Andrick B, et al. Demodex folliculorum infestation mimicking acute cutaneous GVHD. Biol Blood Marrow Transplant. 2020 March; 26(3): S342. doi: https://doi.org/10.1016/j.bbmt.2019.12.374. Link
• Marjoncu D, Andrick B. Gilteritinib: a novel FLT3 inhibitor for relapsed/refractory acute myeloid leukemia. J Adv Pract Oncol. 2020 Feb;11(1):104–108. doi: https://doi.org/10.6004/jadpro.2020.11.1.7. Link
• Tunzo N, Andrick B. Using the FINER criteria to evaluate your research question. Pennsylvania Pharmacist. 2019 September/October. Vol 100, Issue 5. Link
• Andrick B, Gulbis A, Urban T. How to Engage Your Local Legislator. ASTCT Pharmacy Special Interest Group Newsletter. Summer 2019:Vol 7, Issue 2.
• Vadakara J, Andrick B. Current advances in hodgkin’s lymphoma. Chronic Dis Transl Med. 2019; 5(1):15–24. Link
• DeRemer C, Andrick B, Marie Capito. Clozapine drug-induced pancreatitis of intermediate latency of onset confirmed by de-challenge and re-challenge. Int J Clin Pharmacol Ther. 2019;57(1):37-40. Link
• Andrick B, Alwhaibi A, DeRemer DL, et al. Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib. Br J Haematol. 2018;182(5):712-714. Link
• Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, DeRemer D. Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: The FOND-O Trial. Biol Blood Marrow Transplant. 2018; 24(10):2065-2071. Link
• Andrick B, Gandhi A. Olaratumab: A novel platelet-derived growth factor receptor α-inhibitor for advanced soft tissue sarcoma. Ann Pharmacother. 2017;51(12):1090-1098.https://pubmed.ncbi.nlm.nih.gov/28778132/• Andrick B. Anti-emetic prophylaxis updates in HCT. ASBMT Pharmacy SIG Newsletter. Winter 2017: Volume 5, Issue 1.
• Andrick B, Alwhaibi A, DeRemer D, et al. Antibody response to pneumococcal conjugate vaccine (PCV13) in chronic lymphocytic leukemia patients receiving ibrutinib. Blood. 2016;128(22):5597. doi: 10.1182/blood.V128.22.5597.5597 Link
• O’Donnell LA, Meng WS, Andrick B, Borello AM. A bioinformatics practicum to develop student understanding of immunological rejection of protein drugs. Am J Pharm Educ. 2016;80(9):147. doi: 10.5688/ajpe809147 Link
• Andrick B, Anderegg S. New ‘Biosimilars’ may help reduce medication costs. ASHP SafeMedication. February 2016. 
• Andrick B, Schwab AI, Cauley B, O’Donnell LA, Meng WS. Predicting hemagglutinin MHC-II ligand analogues in anti-TNFα biologics: implications for immunogenicity of pharmaceutical proteins. PLoS One. 2015;10(8):e0135451. doi: 10.1371/journal.pone.0135451. Link
• O’Donnell L, Andrick B, Meng W. Design of a bioinformatics practicum aimed at integrating concepts in immunology, virology, and pharmaceutical sciences in pharmacy curricula. J Immunol:2014;192(1 Supplement)49.7. Link

Publications:

• Farley S, Cummings C, Heuser W, et al. (2019). Prevalence and over testing of true heparin-induced thrombocytopenia in a 591-bed tertiary care, teaching hospital. J Intensive Care Med. 2019;34(6), 464–471. Link
• Farley S, Gottesman MH, Friedman-Urevich S, et al. Anti-John Cunningham virus antibody index levels in multiple sclerosis patients treated with rituximab, fingolimod, and dimethyl fumarate. Surg Neurol Int. 2019;10:59. doi: 10.25259/SNI-4-2019 Link
  

• Heffelfinger A, Brickett L, Farnham K, Slampak-Cindric A. Safety and effectiveness of fixed-dose 4FPCC versus weight-based dosing for the reversal of warfarin. Poster presented at: 2020 American College of Clinical Pharmacy Virtual Poster Symposium.
• Heffelfinger A, Brickett L, Farnham K, Slampak-Cindric A. Efficacy of an adjusted body weight heparin nomogram for deep vein thrombosis and pulmonary embolism in obese patients. Poster presented at 2019 American Society of Health-System Pharmacists Midyear Clinical Meeting; Las Vegas, NV.
• McGowan M, Slampak-Cindric A, Brickett L. Vitamin C, hydrocortisone, and thiamine for the treatment of severe sepsis and septic shock: a medication utilization evaluation. Poster presented at: 2019 American Society of Health-System Pharmacists Midyear Clinical Meeting; Las Vegas, NV.
• Nguyen K, Seidel R, Hale SF, Slampak-Cindric A. Evaluation of bivalirudin anticoagulation in patients undergoing extracorporeal membrane oxygenation. Poster presented at: 2019 American Society of Health-System Pharmacists Midyear Clinical Meeting; Las Vegas, NV.
• Shoemaker P, Thompson M, Woll N, Slampak-Cindric A. Achieving patient safety expectations during residency training by implementation of a patient safety curricular resource. Poster presented at: the American Board of Medical Specialties Annual Conference; Chicago, Illinois.
• Askey K, Stabinski M, Hale S, Slampak-Cindric A. Antithrombin utilization and monitoring within an integrated health system. Poster presented at: 2018 American Society of Health-System Pharmacists Midyear Clinical Meeting; Anaheim, CA.
• Unger H, Hale S, Slampak-Cindric A. Evaluation of naloxone and flumazenil as reversal agents in acute care hospitals. Poster presented at: 2018 American Society of Health-System Pharmacists Midyear Clinical Meeting; Anaheim, CA

• Mohammad RA, Betthauser KD, Korona RB, Coe AB, Kolpek JH, Fritschle AC, Jagow B, Kenes M, MacTavish P, Slampak-Cindric A, et al. JACCP. 2020. doi:10.1002/jac5.1311. Link
• Slampak-Cindric A. Chapter 148: Pharmacologic principles. In: Layon AJ, Gabrielli A, Yu M, Wood KE, eds. Civetta, Taylor, and Kirby’s Critical Care Medicine. 5th ed. Wolters Kluwer; 2018.
• Tsai C, Slampak-Cindric A, Stamm J. 1872: Use of methylene blue in chemotherapy-induced refractory anaphylactic shock. Crit Care Med. 2016;44(12):543. Doi: 10.1097/01.ccm.0000510545.10589.32. Link